Short answer
Alnylam Pharmaceuticals (ALNY) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $1.2B (up 149.3% year over year) with net income of $251M.
Q3 2025 key financials · XBRL
- Revenue
- $1.2B
- +149.3% YoY · +61.4% QoQ
- Net income
- $251M
- +325.0% YoY · +478.8% QoQ
- Operating margin
- 29.5%
- EPS (diluted)
- $1.90
- +318.4% YoY · +472.5% QoQ
Source: XBRL data from the Alnylam Pharmaceuticals (ALNY) Q3 2025 10-Q on SEC EDGAR. USD.
Alnylam Pharmaceuticals Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin data provided for current quarter or YoY comparison
- Cash, equivalents, marketable securities, and Revolving Credit Agreement availability deemed sufficient for next 12 months as of Sept 30, 2025
- Management warns potential need for significant additional funds earlier due to development and commercialization risks
Risk Factors
- New risk: AMVUTTRA U.S. launch March 2025 for ATTR amyloidosis with cardiomyopathy increases commercialization risk
- Updated financial risk: Accumulated deficit $7.16B as of Sept 30, 2025; product revenues $851.1M Q3, $1.99B YTD with ongoing operating losses
- Regulatory risk: Ongoing regulatory oversight plus potential liability from unapproved product promotion or off-label marketing
- Operational risk: Dependence on collaborators Roche, Regeneron, Novartis, Sanofi for development, commercialization, and sales execution
- Financial risk: $2.72B cash and equivalents exposed to credit, liquidity, market risks; significant foreign currency exposure especially JPY, EUR, GBP impacting revenues and expenses
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Alnylam Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.